Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has become the first listed company in the A-share market to release its 2025 annual report, indicating the start of the annual performance reporting period for the market. This reflects the company's strong governance, internal control quality, and commitment to transparent information disclosure, showcasing management's confidence in operational quality and financial health [2] Financial Performance - In 2025, Wohuah Pharmaceutical achieved total operating revenue of 817 million yuan, a steady increase of 6.96% year-on-year. The net profit attributable to shareholders reached 95.7153 million yuan, a significant increase of 162.93%, marking the highest growth rate in nearly a decade. Notably, the net profit growth rate significantly outpaced revenue growth, indicating a structural improvement in profitability and quality of growth [2][3] Strategic Initiatives - The company has consistently adhered to a strategy of maintaining a strong exclusive product line. In response to deepening industry policies and increasing market competition, Wohuah Pharmaceutical has built competitive barriers through its exclusive products, including Wohuah® Xinkeshu tablets and other key products, enhancing market competitiveness [3] - The net profit growth exceeding revenue growth is attributed to the premium capability of high-value product combinations and refined cost control, demonstrating the resilience of the product line across policy cycles [3] Cash Flow and Financial Health - During the reporting period, the net cash flow from operating activities increased by 40.45%, and the asset-liability structure remained highly stable with zero interest-bearing debt. This reflects the company's excellent financial health and strong internal cash generation capability, providing a solid foundation for sustainable operations and strategic initiatives [3] Dividend Policy - The board of directors approved a cash dividend plan, proposing a distribution of 1.46 yuan (tax included) for every 10 shares. This move demonstrates management's confidence in the company's future profitability and cash position, as well as a commitment to shareholder returns under a "zero interest-bearing debt" operational model [4] Future Outlook - Looking ahead to 2026, Wohuah Pharmaceutical plans to deepen its focus on traditional Chinese medicine, emphasizing the clinical value and market synergy of its exclusive product line. The company aims to respond prudently to ongoing procurement policies and actively expand its outpatient market while enhancing research and access strategies [4]

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, despite a challenging industry environment [2] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total revenue of 817 million yuan, representing a year-on-year growth of 6.96% [2] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [2] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [2] Group 2: Strategic Initiatives - The company has maintained a "strong exclusive product line" strategy, focusing on proprietary products in the cardiovascular and chronic disease sectors [2] - Wohuah Pharmaceutical plans to implement a strategic optimization and restructuring of its production system in 2025, aiming for efficient integration and cost reduction [3] - The company intends to deepen its focus on proprietary product lines and enhance clinical value and market synergy while responding to ongoing procurement policies [3] Group 3: Future Outlook - Wohuah Pharmaceutical aims to strengthen its research and access strategies, leveraging a solid financial structure for potential capital operations around its core business [3] - The company is expected to continue benefiting from favorable policies supporting the traditional Chinese medicine market, which is projected to maintain rapid growth [3]

沃华医药（002107）(002107.SZ)发布2025年年度报告，该公司营业收入为8.17亿元，同比增长6.96%。 归属于上市公司股东的净利润为9571.53万元，同比增长162.93%。归属于上市公司股东的扣除非经常性 损益的净利润为9210.67万元，同比增长168.20%。基本每股收益为0.17元。此外，拟向全体股东每10股 派发现金红利1.46元(含税)。 ...

Core Viewpoint - Wohua Pharmaceutical (002107.SZ) reported a revenue of 817 million yuan for the year 2025, reflecting a year-on-year growth of 6.96% [1] - The net profit attributable to shareholders reached 95.71 million yuan, marking a significant increase of 162.93% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 92.11 million yuan, up by 168.20% year-on-year [1] - The basic earnings per share stood at 0.17 yuan [1] - The company proposed a cash dividend of 1.46 yuan (including tax) for every 10 shares to all shareholders [1]

新京报贝壳财经讯 1月19日，沃华医药公告，公司2025年度合并报表归属于上市公司股东的净利润 9571.53万元，母公司可供股东分配利润为9125.95万元。公司可供股东分配利润为8466.1万元。公司拟 以2025年12月31日的总股本5.77亿股为基数，向全体股东每10股派发现金红利人民币1.46元(含税)，共 计派发现金红利8427.26万元(含税)，不送红股，不以公积金转增股本。本利润分配预案实施后，公司 2025年度累计现金分红总额为1.54亿元，占本年度归属于上市公司股东的净利润160.41%。 ...

沃华医药公告，公司2025年度合并报表归属于上市公司股东的净利润9571.53万元，母公司可供股东分 配利润为9125.95万元。公司可供股东分配利润为8466.1万元。公司拟以2025年12月31日的总股本5.77亿 股为基数，向全体股东每10股派发现金红利人民币1.46元（含税），共计派发现金红利8427.26万元（含 税），不送红股，不以公积金转增股本。本利润分配预案实施后，公司2025年度累计现金分红总额为 1.54亿元，占本年度归属于上市公司股东的净利润160.41%。 ...

格隆汇1月19日丨沃华医药(002107.SZ)公布2025年年度报告，报告期内，公司实现营业收入81,695.24万 元，同比增长6.96%；实现归属于上市公司股东的净利润9,571.53万元，同比增长162.93%。主要产品线 中，心脑血管系统药品营业收入56,880.65万元,同比增长12.31%；肌肉骨骼系统药品营业收入18,250.42 万元，同比下降2.03%；抗病毒类呼吸系统药品营业收入2,609.23万元，同比增长18.46%。向全体股东 每10股派发现金红利1.46元。 ...

Core Insights - Shandong Wohua Pharmaceutical reported a revenue of 817 million yuan for the fiscal year 2025, marking a year-on-year increase of 6.96% [1] - The net profit attributable to shareholders reached 95.71 million yuan, a significant increase of 162.93%, the highest growth rate in nearly a decade [1] Financial Performance - The company's operating cash flow increased by 25% year-on-year, indicating strong cash generation capabilities [2] - The asset-liability structure remains robust, with zero interest-bearing debt [1] Strategic Initiatives - Wohua Pharmaceutical plans to implement a cash dividend scheme of 1.46 yuan per 10 shares, building on a previous dividend of 1.20 yuan [2] - The company announced a strategic optimization and restructuring of its production system to achieve cost reduction through resource synergy and intelligent upgrades [2] Future Outlook - For 2026, the company aims to deepen its focus on traditional Chinese medicine, respond effectively to ongoing procurement policies, and expand its outpatient market [2] - Wohua Pharmaceutical will enhance its research and access strategies, aiming for operational efficiency through meticulous management practices [2]

沃华医药公告，2025年营业收入8.17亿元，同比增长6.96%。净利润9571.53万元，同比增长162.93%。 公司董事会审议通过的利润分配预案为：以5.77亿股为基数，向全体股东每10股派发现金红利1.46元 （含税），送红股0股（含税），不以公积金转增股本。 ...

山东沃华医药科技股份有限公司 审计报告 中喜财审 2026S00005 号 中喜会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ag.com 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ag.cng.cn/ ( ) ZHONGXI CPAs SPECIAL GENERAL PARTNERSHIP 2026S00005 地址： 北京市崇文门外大街 11 号新成文化大厦 A 座 11 层 邮编： 100062 电话：010-67085873 传真：010-67084147 邮 箱： zhongxi@zhongxicpa.net 1-5 6-90 2025 12 31 2025 2025 12 31 2025 1 1 1 1 A 1 1 010-67085873 010-67084147 100062 ( ) ZHONGXI CPAs SPECIAL GENERAL PARTNERSHIP 26. 2025 81,695.24 2 1 2 4 5 1 21 2025 12 31 4,604.54 1,353.67 3,250.87 2 ...